Nuocheng Jianhua (688428.SH): The application for marketing authorization of Tafasitamab in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma has been approved in China.

Zh tng cijng APP xn, nu chng jin hu (688428.SH) fb gnggo, gngs shudo guji yopn jind gunl j (NMPA) de tngzh, gngs bxing CD19 de chnpn tn x tu dn kng (tafasitamab) (shngpn mng: mng nu ki ) linh li n d n zhlio b shh zt gn xbo y zh tiojin de ff / nnzhxng mhn xng d B xbo lnbylero (yxi jinchng "r/rDLBCL") chngxn d rn hunzh de shngsh shnqng hud pzhn, zh sh zhnggu shu g hu p zhlio r/rDLBCL de CD19 dnkng.